Crealta Pharmaceuticals LLC
Crealta Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for rare diseases. Founded in 2013, the company has made significant strides in developing treatments that address unmet medical needs, particularly in the areas of pain management and rare conditions. Crealta's flagship product, Krystexxa, is a unique enzyme therapy designed for chronic gout patients who are refractory to conventional treatments. This product has positioned Crealta as a leader in the gout treatment market, showcasing the company's commitment to improving patient outcomes through advanced biopharmaceutical solutions. With a focus on research and development, Crealta continues to expand its portfolio, solidifying its reputation as a trusted name in the healthcare sector.
DitchCarbon Score
How does Crealta Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Crealta Pharmaceuticals LLC's score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Crealta Pharmaceuticals LLC's reported carbon emissions
Crealta Pharmaceuticals LLC, headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, the company has not outlined any specific reduction targets or initiatives related to climate commitments. In the absence of concrete emissions data or defined climate strategies, it is unclear how Crealta Pharmaceuticals is addressing its environmental impact. As the pharmaceutical industry increasingly focuses on sustainability, it is essential for companies like Crealta to establish measurable climate goals and transparent reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Crealta Pharmaceuticals LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
